KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Other Non Operating Income (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Other Non Operating Income for 13 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non Operating Income rose 2004.99% year-over-year to $11.1 million, compared with a TTM value of $11.6 million through Dec 2025, up 448.95%, and an annual FY2025 reading of $11.6 million, up 448.95% over the prior year.
  • Other Non Operating Income was $11.1 million for Q4 2025 at Travere Therapeutics, up from $487000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $11.1 million in Q4 2025 and bottomed at -$7.6 million in Q1 2022.
  • Average Other Non Operating Income over 5 years is $126555.6, with a median of $162500.0 recorded in 2023.
  • The sharpest move saw Other Non Operating Income crashed 1638.81% in 2024, then soared 2004.99% in 2025.
  • Year by year, Other Non Operating Income stood at -$875000.0 in 2021, then surged by 169.49% to $608000.0 in 2022, then skyrocketed by 125.99% to $1.4 million in 2023, then tumbled by 142.29% to -$581000.0 in 2024, then skyrocketed by 2004.99% to $11.1 million in 2025.
  • Business Quant data shows Other Non Operating Income for TVTX at $11.1 million in Q4 2025, $487000.0 in Q3 2025, and -$526000.0 in Q2 2025.